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Abstract 
Hydrogels have attracted considerable attention due to numerous applications, in particular as 
contact lenses and carriers for sustained drug delivery. The aim of the present work is to characterize 
the interactions of copolymer hydrogels consisted of 2-hydroxyethylmethacrylate (HEMA) and 2-
hydroxyethylacrylate (HEA) with a small protein (lysozyme) and to assess the potential applications 
of these hydrogels as a drug delivery system for sustained release of protein-based therapeutics.  
Physicochemical properties of protein-loaded hydrogels, as well as lysozyme in vitro loading and 
release and the conformation of the protein released from hydrogels were studied. The effect of 
copolymer composition on the protein deposition on hydrogels and protein aggregation in the 
presence of hydrogels was also assessed.  The results show that introduction of HEA into the 
copolymeric hydrogels enhances their suitability as a delivery system for proteins. Copolymerisation 
of HEMA and HEA allows controlling the physicochemical properties of hydrogels and the protein 
release rate. 
 
Abbreviations: HEA - 2-hydroxyethylacrylate; HEMA - 2-hydroxyethylmethacrylate; DSC - 
Differential Scanning Calorimetry; TGA - Thermogravimetric Analysis; TA – Texture Analysis; 
FTIR - Fourier-transform infrared spectroscopy; SEM - Scanning Electron Microscopy; OD – 
optical density; ThT – Thioflavin T 
2 
 
1. INTRODUCTION 
Hydrogels are three-dimensional polymeric hydrophilic networks, capable of imbibing large amount 
of water [1]. Due to their biocompatibility and  resemblance to natural living tissue, hydrogels have 
found numerous applications in medicine and pharmaceutical science, including soft contact lenses, 
carriers for controlled drug release, tissue engineering scaffolds, and matrices for enzyme 
immobilisation [1, 2, 3]. 
 
Proteins are widely used as therapeutic agents (recombinant proteins with enzymatic or regulatory 
activity, monoclonal antibodies, bacterial protein antibiotics, vaccines [4, 5] and there is great 
potential for further development of new protein-based pharmaceuticals [6, 7, 8]. Proteins can also 
be employed as drug delivery agents in protein-based nanoparticles. Unlike synthetic polymers, 
natural biomolecules present a number of advantages including safety, biocompatibility and 
biodegradability [9]. Low molecular weight proteins such as lysozyme have also been shown as 
suitable carriers to target drugs to the kidney [10 and references therein]. For clinical applications 
the most commonly used small proteins are growth factors and cytokines (wound healing) [11] and 
transcription factors (regulatory proteins in gene expression) [12]. 
 
One of the main problems, which protein pharmaceutics face, is that the serum half-life of 
recombinant proteins is sometimes insufficiently short as they can be rapidly cleared thus requiring 
frequent administration. Administering drugs locally rather than systemically using sustained release 
can be a way to extend their serum half-life and to decrease drug toxicity. Hydrogels potentially can 
be used as carriers for protein pharmaceutics for topical applications (for example, for a topical 
antibacterial treatment for a localized infection) and also for oral delivery [13, 14, 15]. 
 
Recently we described the hydrogels prepared by free-radical three-dimensional copolymerisation of 
2-hydroxyethylmethacrylate (HEMA) and 2-hydroxyethylacrylate (HEA) [ 16 , 17 ]. We have 
demonstrated that introduction of hydrophilic HEA significantly changes the morphology and the 
physicochemical properties of the HEA-HEMA hydrogels. In order to evaluate the HEA-HEMA 
hydrogels as potential drug delivery systems for sustained release of large biopharmaceuticals, the 
interaction of hydrogel networks with a model protein (lysozyme) needs to be investigated since the 
addition of drug molecules (especially large macromolecules like proteins) can adversely affect the 
physicochemical properties of the hydrogels.  
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At the same time, in the “hydrogel – protein” system, a hydrogel, in its turn, can have an impact on 
the protein behaviour when incubating in a protein solution during loading. In many biomedical 
applications (contact lenses, blood-contacting implants, drug delivery devices, and artificial organs), 
hydrogels can be in a prolonged contact with proteins. This contact can be either planned if 
hydrogels are used as drug delivery systems loaded with biopharmaceutical proteins (therapeutic 
agents) or unwanted but unavoidable (contact with body liquids, i.e. tears or blood, enriched with 
proteins). In the latter case proteins can be considered as a contamination. When exposed to a solid 
surface, protein molecules have a tendency to rearrange their 3D structure and adsorb on the surface 
in order to lower the Gibbs energy [18]. A protein layer begins to form immediately after hydrogel 
exposure to a protein solution [19]. This problem is especially important for contact lenses – a 
protein film formation on the lens surface due to the protein deposition leads to lens spoilage [20, 21, 
22]. The latter may cause allergic and inflammatory responses in lens wearers. Lysozyme is the 
most abundant protein in human tears (about 30% of the tears total protein content) followed by 
lactoferrin and tear albumin [23]. It was found that lysozyme is the most prevailing protein in the 
protein films on the lens surface due to its low molecular weight and positive charge at 
physiological pH [21, 24, 25, 26]. At the same time a protein contact with the hydrogel surface can 
also result in partial rearrangements of the protein’s native 3D structure and protein destabilisation / 
unfolding. In its turn, protein unfolding facilitates protein aggregation [27]. Thus, a contact with 
hydrogel surface can potentially lead to the protein destabilization and aggregation. 
 
In the present work we studied HEA-HEMA hydrogels interactions with a protein, which can be 
considered from two different points of view: (1) the protein as a drug, which could be delivered 
using these hydrogels; and (2) the protein in the body liquids (tears or blood) that could interact with 
the hydrogels. To combine these two aspects, lysozyme has been chosen as a model protein as it is a 
relatively small biopolymer, which is present in the human body fluids, especially it is abundant in 
the tear fluid. Moreover, lysozyme is also known as a protein able to form a protein film on different 
types of contact lens and, therefore, can serve as a good model to study the effect of HEA-HEMA 
hydrogel composition on protein deposition. In the first part of the study the impact of protein 
(lysozyme) on different physicochemical and pharmaceutical properties of HEA-HEMA hydrogels 
was studied and compared with the protein-free hydrogels. Physicochemical (swelling, morphology, 
the total water content, free/bound water distribution and water retention) and mechanical properties 
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of hydrogels loaded with lysozyme were examined using SEM, FTIR, TGA, DSC, gravimetry and 
texture analysis. Lysozyme in vitro loading/release and the conformation of the protein released 
from HEA-HEMA hydrogels with different HEA content were analysed using UV-Vis, FTIR, and 
Thioflavin T assay. In the second part of the study in order to develop materials with the minimised 
adverse effects resulting from protein interaction with hydrogels, the effect of hydrogels on the 
protein was assessed. Specifically, in this part of work we investigated two possible aspects related 
to the hydrogel effect on proteins: protein deposition onto HEA-HEMA hydrogels; and protein 
aggregation in the presence of HEA-HEMA hydrogels.  
 
 
2. EXPERIMENTAL 
2.1 Materials 
The 2-hydroxyethylacrylate-co-2-hydroxyethylmethacrylate (HEA-HEMA) hydrogels with different 
HEA-to-HEMA ratios (HEA content varied from 0 to 100 mol %) were synthesized by three-
dimensional free-radical copolymerisation of HEA and HEMA, purified and freeze-dried as 
described previously [16]. Hereinafter the hydrogels are labelled according to the HEA mol % 
content in the monomer feed mixture. 
 
10X PBS buffer (pH 7.4) was obtained from Gibco® (UK). Lysozyme from chicken egg white and 
Thioflavin T were obtained from Sigma-Aldrich (UK). Unless otherwise specified, all materials and 
reagents used were of analytical grade and were used without further purification. 
 
Freeze-dried HEA-HEMA hydrogel samples were immersed in an excessive volume of the liquid 
media (150 mM PBS buffer or freshly prepared lysozyme solution in 150 mM PBS) and allowed to 
fully swell during 10-14 days until the mass of hydrogel became constant over time. Samples were 
kept at 4 °C all the time to prevent protein denaturation. The sterile water has been used to prepare 
the protein solutions and the absence of protein denaturation or aggregation over 14 days of 
incubation at 4 °C was confirmed spectrophotometrically.  
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2.2 Methods 
2.2.1 Swelling of HEA-HEMA hydrogels  
The swelling measurements of the HEA-HEMA hydrogels with different HEA content in 150 mM 
PBS buffer (pH 7.4) containing lysozyme (10 mg/mL) were performed by conventional gravimetric 
analysis. In a typical experiment a pre-weighed piece of freeze-dried hydrogel (30 ± 10 mg) was 
immersed into a swelling medium at 4 °C and allowed to swell. At regular time intervals swollen 
hydrogels were quickly took out from the swelling medium (excess water was removed by blotting a 
sample against plastic weighing boat), weighed and placed in the same medium. The procedure was 
continued until the equilibrium has been achieved (i.e. until the weight of hydrogel was found to 
remain constant). Between measurements the samples were kept at constant temperature (4 °C). The 
swelling degree (SD%) was calculated as follows: 
%100% 


d
ds
W
WW
SD         (1) 
where Ws is the weight of a swollen hydrogel; Wd is the weight of a dry hydrogel. 
 
2.2.2 Thermogravimetric analysis (TGA) 
The dynamic weight loss by the fully swollen hydrogels samples and the total amount of water in 
the samples were measured using the Perkin Elmer Pyris 1 Thermogravimetric Analyzer (USA). All 
tests were conducted in a N2 gas purge (20 mL/min).  In a temperature scan experiment a hydrogel 
sample (25-30 mg) in a sealed and perforated (non-hermetic) aluminium pan was exposed to heat at 
a rate of 5 °C/min in the 25-250°C temperature range. Onset and end set temperatures of water 
evaporation were calculated using Pyris software. 
 
In a separate type of experiments (“loss-on-drying” experiments [17]), the rate of water evaporation 
from a hydrogel sample at physiological temperature was measured by incubating the fully swollen 
hydrogel sample (about 25-30 mg) in an open aluminium pan at 37 °C during 120 min and 
measuring weight loss over time. After 2 h isothermal incubation, the sample was heated from 37 °C 
to 250 °C at 5 °C/min. Water evaporated during incubation at 37 °C and the total amount of water in 
hydrogel samples were calculated. 
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2.2.3 Differential scanning calorimetry (DSC) 
The thermal properties of the hydrogels were examined using the Perkin-Elmer Jade DSC (USA). A 
fully-swollen hydrogel sample (about 11 ± 2 mg) was placed in an aluminium pan and the pan was 
hermetically sealed. An empty pan was used as a reference. The samples were cooled from 30 to – 
40 °C at 2 °C/min and held for 3 minutes before returning back to 30°C at the same rate. Nitrogen 
was used as a purge gas at 20 mL/min. The calorimeter was calibrated using indium standard. The 
melting/crystallisation temperatures and enthalpy of melting/crystallisation for water in hydrogels 
were calculated using Pyris software. 
 
2.2.4 Fourier-transform infrared spectroscopy (ATR-FTIR) 
To assess the secondary structure of lysozyme released from hydrogels, the Attenuated Total 
Reflectance FTIR spectroscopy was used. IR spectra were recorded over the wavelength range 
4000-500 cm-1, with a resolution of 2 cm-1 and 70 scans accumulation, using an FTIR Platinum-ATR 
spectrometer (Bruker Tensor OPUS 27 FT-IR’). The spectra were corrected for the baseline. To 
prepare lysozyme samples for FTIR, hydrogels with different HEA content loaded with lysozyme 
were placed in 1 mL of distilled water and kept 1-2 days at 4 °C. Then lysozyme concentration in 
solution was measured and solutions containing lysozyme released from the hydrogels were freeze-
dried. Freshly prepared lysozyme aqueous solution of the same concentration was also freeze-dried 
using the same cycle and taken as a control. After lyophilisation samples were stored at 4 °C in dry 
atmosphere no longer than 48 hours prior to the measurements. 
 
2.2.5 UV-Vis absorption spectroscopy 
UV-Vis absorption spectra or single wavelength absorbance of lysozyme in 150 mM PBS buffer 
were recorded using a Thermo-Scientific UV-Vis Evolution 60S spectrophotometer in 1-cm path-
length quartz cuvettes, at room temperature (22 °C). The absorption spectrum of the solvent (PBS 
buffer) was subtracted from the solution absorption spectrum. Protein concentration was calculated 
from the absorbance of the lysozyme solution at 280 nm using a percent solution extinction 
coefficient of 26.4 E1%. 
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2.2.6 In vitro protein loading and release assays  
In a typical protein loading experiment, a pre-swollen hydrogel sample (20-50 mg) was weighed and 
immersed into an excessive volume of the lysozyme solution (in 150 mM PBS buffer, pH 7.4) at 
given temperature (4 °C or 22 °C).  After a fixed time interval the hydrogel sample was very briefly 
(< 1 sec) rinsed in PBS buffer to remove the excessive protein solution from the hydrogel surface, 
transferred into a fresh aliquot of PBS buffer (2 mL) and kept at 4 °C. After 24-48 hours the 
concentration of protein released was measured spectrophotometrically at 280 nm.  
 
Release studies of the lysozyme have been carried out in vitro by placing a fully swollen and 
lysozyme-loaded hydrogel sample (about 20 ± 1.5 mg) in a fixed volume (2 mL) of the release 
medium (150 mM PBS buffer) at room or low (4 °C) temperature. Before placing in the release 
medium the hydrogel sample was very quickly (< 1 sec) pre-washed in small volume (< 100 μL) of 
release medium to remove surface water containing extra proteins. The amount of protein released 
was measured spectrophotometrically at 280 nm at regular time intervals. The liquid volume was 
kept constant during the measurement.  
 
2.2.7 Protein aggregation 
To induce protein aggregation, lysozyme solutions were pre-incubated at room temperature (22 °C) 
or at 45 °C for 2-5 days. Turbidimetry assay at 360 nm was used to assess the formation of protein 
aggregates. The presence of aggregates was also confirmed using light microscopy.  
 
2.2.8 Fluorescence spectroscopy 
ThT assay was used to assess the presence of protein aggregates in solutions. In a typical experiment 
20µL of 1 mM Thioflavin T (ThT) was added to 2 mL solutions of lysozyme in PBS buffer 
immediately prior to the measurements. The ThT fluorescence emission spectra were recorded using 
a LS55 spectrofluorometer (Perkin-Elmer, UK). The temperature inside the 1-cm quartz cuvette was 
maintained at 24.5 °C by a thermostated cell holder. 
ThT emission spectra were recorded in 0.5 nm increments by exciting the sample at 445 nm and 
collecting the emission between 455 and 650 nm; the excitation and emission slit widths were set at 
2.5 and 5 nm, respectively. Final ThT concentration was 10 µM, and for lysozyme – 10 mg/mL.  
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2.2.9 Texture Analysis 
Mechanical properties of fully swollen (in either 150 mM PBS buffer alone or buffered 2 mg/mL 
lysozyme solution) HEA-HEMA hydrogels were studied using Texture Analyser (Stable Micro 
System TA-XT.plus) in compression mode. A stainless steel cylindrical P/2 probe with a diameter 
of 2 mm was pressed into a hydrogel sample and compression force change with distance/time was 
monitored. The probe pre-test speed of 1 mm/s, test speed of 0.5 mm/s and trigger force of 0.2 g 
were used and the distance target mode with a distance of 1.5 mm was set up during all experiments. 
The value of stress (the force per unit area) was calculated from the maximum force value:  
𝑆𝑡𝑟𝑒𝑠𝑠 =
𝐹𝑜𝑟𝑐𝑒 (𝑔)
𝐴𝑟𝑒𝑎 (𝑚𝑚2)
         (2) 
Each hydrogel sample was measured at room temperature 5-7 times and the average value of stress 
was taken. After penetrating  hydrogel sample, the probe was held for 20 sec before releasing the 
pressure (“on hold” stage) and the force relaxation was calculated as ratio between the forces before 
and after “on hold” stage. 
 
2.2.10 Scanning Electron Microscopy (SEM) 
The surface morphology of HEA-HEMA hydrogels swollen in PBS buffer in the presence of 
lysozyme was examined using Carl Zeiss EVO HD15 Scanning Electron Microscope (UK) with the 
Peltier Coolstage MK3 (DEBEN UK Ltd) at various magnifications (up to 10K). The temperature 
and pressure inside the sample chamber were -21 oC at 10-15 Pa, respectively. A gel sample was 
mounted on pre-chilled 12.5 SEM pin metal stub and quickly frozen before images were collected.  
 
To examine the protein deposition, the hydrogels samples were stored for 1.5 months at room 
temperature (22 °C) in 150 mM PBS buffer (pH 7.4) containing lysozyme (2 mg/mL), followed by 2 
years storage at 4 °C. Hydrogel samples were briefly rinsed in PBS to remove unbound material 
before being placed on pre-chilled SEM metal stubs. 
 
 
3. RESULTS AND DISCUSSION 
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3.1 Effect of lysozyme on physicochemical properties of HEA-HEMA hydrogels loaded with 
lysozyme 
3.1.1 HEA-HEMA hydrogels swelling in the presence of lysozyme in buffer solution 
The equilibrium swelling degrees of HEA-HEMA hydrogels (with and without lysozyme) as a 
function of the HEA content in polymeric network are presented in Fig. 1 (a). For both samples the 
equilibrium swelling degree depends strongly on the ratio between co-monomers (HEA and HEMA) 
in the hydrogel network and reveals non-linear behaviour. A moderate increase in the swelling 
degree occurs for hydrogel compositions with HEA ≤ 40 mol %, whereas the HEA-rich samples 
(HEA ≥ 70 mol %) show the most significant increase in the equilibrium swelling degree (around 
1300 %), thus imbibing 7-10 times more liquid than HEMA-rich hydrogels.  
 
Generally, variation in the swelling degree is related both to the difference in the hydrophobicity of 
HEA and HEMA monomers (as a more hydrophilic monomeric unit lacking extra methyl group, 
HEA is able to attract more water favouring the osmotic water diffusion into the hydrogel matrix) 
and the mesh size of the polymeric network (i.e. distance between the cross-links) obtained during 
hydrogel synthesis. As it was estimated previously [16], the molecular weight between the cross-
links in HEA-HEMA hydrogels varied from ~270g/M (i.e. ~2 monomers) for Poly-HEMA to 
~50,000 g/M for Poly-HEA (i.e ~435 monomers).   
 
Results shown in Fig. 1 (a) also reveal that the general character of HEA-HEMA hydrogels swelling 
in aqueous [16, 17] and in buffered solutions with or without protein is similar with only a minor 
decrease in the swelling degree for the hydrogels swollen in the presence of lysozyme. Thus, the 
swelling degree of the hydrogels is determined mainly by the hydrogel composition.   
 
The kinetics of the hydrogel swelling (Fig. 1 (a, insert), only examples for HEA50 and HEA 80 are 
shown) in buffered solutions containing lysozyme shows that more hydrophilic HEA-rich hydrogels 
(HEA content 80 mol %) reach the swelling equilibrium faster. To elucidate the mechanism of fluid 
diffusion into the polymer matrix during hydrogel swelling in protein solution, the diffusion 
exponents n were estimated using Ritger-Peppas equation [28]: 
     nt kt
M
M

0
     (3) 
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where Mt and M0 are the amount of water absorbed by the hydrogel at time t and at equilibrium, 
respectively, k is a characteristic constant of the system and n is a characteristic exponent of the 
mode of water transport [1]. The value of the diffusion exponent n has been shown to be dependent 
on the rates of liquid diffusion into the polymer matrix and polymer relaxation [1, 29, 30]. If n=0.5 
the case corresponds to the Fickian diffusion-controlled mechanism (where the rate of water 
diffusion is lower than the rate of relaxation of the polymer chain); if 0.50 < n < 1, the non-Fickian 
diffusion takes place (when the water diffusion and chain relaxation rates are comparable); if n < 0.5, 
the case is regarded as Fickian diffusion (but “less Fickian” when the water penetration rate is much 
below the polymer chain relaxation rate [31]). 
 
Re-writing equation (3) in a form 
tnk
M
M t lnlnln 
0
     (4) 
allows estimating the coefficient n from the swelling kinetics curves re-plotted in logarithmic 
coordinates ln(Mt/M0) vs. ln(t). Initial parts of the ln(Mt/M0) vs. ln(t) dependencies (where the 
swelling fraction Mt / M0 ≤ 0.6) were fitted with linear function and the gradient values 
corresponding to the diffusion exponent n according to Eq. (4)) were plotted against the HEA 
content (Fig. 1 (b)). As is seen, HEMA-rich samples (HEA < 70 mol %) revealed “less Fickian” 
type of diffusion of liquid into hydrogels (n in the range of 0.33 - 0.45). HEA-rich hydrogels (HEA 
> 80 mol %) show non-Fickian type of diffusion (0.5 < n < 1) meaning that their swelling is a chain 
relaxation-controlled process (the water diffusion is much faster than the rate of relaxation). HEA-
rich hydrogels can absorb water very quickly due to larger pores and hydrophilic nature of HEA 
whilst the hydrogels with higher proportions of HEMA are more hydrophobic in nature and more 
cross-linked; therefore, it takes longer to hydrate the polymer network and the swelling kinetics 
depends on the rate of water diffusion as well as on the polymer chain relaxation rate. 
 
The comparison of the swelling mechanisms in aqueous and in protein solutions also confirmed that 
hydrogel swelling is identified mainly by the monomer composition even in the presence of protein 
in liquid phase. The equilibrium swelling degree is slightly reduced in the presence of protein.   
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3.1.2 Morphology of HEA-HEMA hydrogels in buffered solutions containing lysozyme   
The internal structure of HEA-HEMA hydrogels fully swollen in PBS buffer containing lysozyme 
was examined using SEM (Fig. 2 (a-d)). Analysis of the SEM micrographs of hydrogels reveals that 
in buffered solution containing lysozyme all hydrogels have a porous structure which is highly 
dependent on the HEA content in the copolymer. PHEMA hydrogels are rather dense with thick 
polymer “walls” (10 – 50 μm) and a number of poorly interconnected large pores (15-35 μm). As 
the HEA content increases, the structure of the hydrogels changes becoming significantly more 
porous; as a result the pore sizes (5 – 10 μm for HEA70) and the thickness of the polymer “walls” 
(0.5 – 1 μm for HEA70) decrease. In the case of HEA-rich hydrogels their pores are highly 
interconnected and occupy the majority (> 80-90%) of the image area. The increased porosity of the 
HEA-rich hydrogels is in line with the increased swelling degree (i.e. water sorption capability) of 
these hydrogels (Fig. 1 (a)). These structural changes are related to the increased interaction between 
more hydrophilic HEA fragments and water molecules. Similar results were obtained for the 
protein-free hydrogels [17]. Thus, comparison of hydrogel porous structures formed in water and in 
lysozyme solution shows that the morphology of the HEA-HEMA hydrogel is mostly defined by the 
copolymer composition whereas the presence of a protein in a swelling medium can only have a 
minute effect on the hydrogel internal structure.  
 
3.1.3 Effect of lysozyme on the total amount of liquid phase in fully swollen HEA-HEMA 
hydrogels 
The addition of large molecules (proteins) can adversely affect the physicochemical properties of 
hydrogels including the total water content. Thermogravimetric analysis was used to determine the 
total water content in fully swollen hydrogels with different HEA content loaded with lysozyme.  
Fig. 3 (a) shows typical TGA thermograms illustrating the hydrogel weight loss with temperature 
due to water evaporation from the samples. The dependencies of the total water content on HEA 
concentration in hydrogels are shown in Fig. 3 (b). The results obtained are in agreement with the 
results on the swelling degree (Fig. 1 (a)): as the HEA content increases, the total amount of water 
imbibed by the hydrogels increases substantially. PHEMA and HEMA-rich samples contain 55-60% 
of liquid phase, whilst HEA-rich samples (HEA ≥ 80) contain about 90% of water. The presence of 
lysozyme has a very little impact on the amount of liquid, which hydrogels can imbibe (Fig. 3 (b), 
curves 1 and 3) confirming that in buffered solutions containing the protein the swelling degree (and 
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the amount of the liquid phase) of the HEA-HEMA hydrogels is determined by the co-polymer 
composition regardless of the loaded macromolecules.  
 
3.1.4 Effect of lysozyme on water retention properties by HEA-HEMA hydrogels  
To study the effect of lysozyme on the hydrogel water retention properties, the weight loss upon 
incubation of swollen hydrogels at physiological temperature (37 °C) was monitored using TGA 
(“loss-on-drying”). After 120 min incubation, hydrogels were heated to 250 °C to evaporate residual 
liquid remained after incubation at 37 °C. Prior to the measurements, hydrogels were fully 
equilibrated either in PBS buffer or in PBS buffer containing lysozyme.  
 
Fig. 4 (a) presents typical ‘loss-on-drying’ TGA weight vs. time curves for different hydrogels 
loaded with lysozyme. Weight of a hydrogel sample decreases upon incubation at constant 
temperature due to water expelling from hydrogel. As is seen, the HEA-rich hydrogels lose almost 
100% liquid during 120-min incubation at 37 °C and further increase in temperature (from 37 to 
250 °C between 120 and 160 min) causes no change in sample weight (Fig. 4 (a)). The HEMA-rich 
hydrogels retain some amount of liquid (~10-15%) after 37 °C incubation (Fig. 4 (b)), which is 
evaporated at following temperature increase from 37 to 250 °C (120 – 160 min time interval). 
Loading with lysozyme has very little impact on the general profiles of water evaporation from the 
hydrogels (Fig. 4(b), curves 1 and 2). Increase of lysozyme concentration up to 30 mg/mL slightly 
decreases the %water loss for HEMA-rich samples and negligibly increases for HEMA50 (Fig. 4b, 
insert).    
  
The effect of the lysozyme concentration in the swelling medium on the water loss was investigated 
using hydrogel samples incubated in lysozyme solutions at 4 °C for at least 5 weeks before the 
measurements (Fig. 4 (b, insert)). The results show that the PHEMA and HEMA-rich hydrogels 
(HEA ≤ 30 mol %) loaded with high concentrations of lysozyme retain slightly (2 – 4 %) more 
water than protein-free samples. As for the HEA-rich hydrogels (HEA ≥ 50 mol %) there are no 
significant differences in the water retention regardless of the lysozyme concentration in solution.  
 
The water evaporation profiles (Fig. 4(a)) show “fast” (initial) and “slow” (subsequent) evaporation 
stages with an “inflection” point (estimated as illustrated in Fig. 4 (a, insert)) separating the stages. It 
is assumed that easily accessible and weakly interacting (or not interacting) with polymer matrix 
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water (i.e. bulk water) is evaporated during the “fast” stage, while bound water is evaporated during 
the “slow” stage [17]. The duration of the fast stage and the amount of fast evaporating water 
strongly depend on HEA content and increase in the case of HEA-rich hydrogels (Fig. 4  (a), (c)) for 
both loaded with lysozyme and protein-free samples. The results obtained clearly correlate with the 
swelling degree of the hydrogels with different HEA content (Fig. 1); the higher the swelling degree 
is and the more water hydrogels can imbibe, the greater the percentage of the fast evaporating water 
(bulk water) in hydrogels is and the longer time is required to evaporate it.  
 
3.1.5 DSC analysis of the thermal properties of water in HEA-HEMA hydrogels swollen in the 
presence of lysozyme  
The thermal behaviour of water absorbed by the hydrogels was studied using DSC. Typical DSC 
thermograms illustrating crystallization (at cooling from 30 to - 40°C) and subsequent melting (at 
heating from -40 to 30 °C) of water in hydrogel samples fully swollen in buffered solutions 
containing lysozyme are shown in Fig. 5(a). For all hydrogel samples the sharp exothermic 
crystallization peak and broad endothermic melting peak were observed. It is well known, that the 
total water in hydrogels can be divided into “freezing” and “non-freezing” water, where “non-
freezing” is related to bound water and “freezing” is associated with free (bulk) water and freezing 
interfacial water [32].  Only the freezing water is responsible for the crystallization and melting 
peaks present in DSC thermograms. Being more hydrophilic, HEA-rich hydrogels imbibe more 
liquid and, therefore, contain more liquid per one unit of hydrogel weight and, consequently, more 
free (freezing) water. As a result, the melting enthalpies increase with HEA content in hydrogels 
(Fig. 5 (b)). 
 
Diffusion of solutes through a hydrogel network depends not only on the total water content but also 
on the binding state of water varying for free and bound water. The combination of DSC-TGA 
methods allows estimating the amount of free and bound water in hydrogels [17] and the effect of 
lysozyme on the redistribution of different types of water. The total amount of water (freezing and 
non-freezing) in hydrogels measured using TGA (Fig. 3) can be represented as a summary of 
freezing and non-freezing water: 
%)100((%)(%) 



pure
freezing
boundtotal
H
H
WW     (5) 
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where Wtotal and Wbound are the amounts of total and non-freezing water in hydrogels equilibrated in 
lysozyme solution, ∆Hfreezing is the melting enthalpy of freezing water (Fig. 5 (b)), ∆Hpure is the 
melting enthalpy of pure water, 334 J g-1 [33]. 
 
The percentage of freezing water in HEA-HEMA hydrogels increases with HEA content both for 
lysozyme-loaded and protein-free hydrogels (Fig. 6). The strongest gain in the amount of freezing 
water was observed when HEA content rises from 30 to 40 mol %, which is in agreement with the 
swelling data (Fig. 1 (a)). Loading with lysozyme reduces the amount of freezing water as some 
water molecules are bound to the protein molecules. However, as the results in Fig. 6 show, 
lysozyme has a minor effect on the free/bound water redistribution across the hydrogels with 
different HEA content. It should be noted that the total amount of water is determined by both 
polymer composition and cross-linking properties (i.e. mesh size), whereas the proportion of non-
freezing and freezing water is mainly dictated by the ratio of hydrophobic and hydrophilic 
monomers, i.e. hydrogel composition.  
 
3.1.6 In vitro loading of lysozyme into and release of lysozyme from HEA-HEMA hydrogels  
The lysozyme loading capacity and the rate of loading for HEA-HEMA hydrogels with low and 
high HEA contents were assessed by placing the swollen hydrogel samples into a buffered protein 
solution for a fixed period of time followed by placing the fragments into a fresh buffer and 
measuring the concentration of protein released. The lysozyme concentration was then recalculated 
for the amount of liquid in hydrogels (Fig. 3 (b)) to estimate the lysozyme concentration inside the 
samples. Fig. 7 (a) shows that HEMA-rich hydrogels upload lysozyme rather slowly as after 24 
hours of incubation in lysozyme solution, the lysozyme concentration in PHEMA was below 10% of 
the lysozyme concentration in solution used to incubate the hydrogels and ascribed to 100%. In 
contrast, the lysozyme concentration in HEA80 is more than 90% of the lysozyme concentration in 
the incubation solution after 24 hours. After 12 days the lysozyme concentrations inside all 
hydrogels were very close to the lysozyme concentration in the solution (Fig. 7 (a)).  
 
As controlled drug release systems, hydrogels are supposed to deliver a drug at a specific rate; 
therefore kinetics of the macromolecules (i.e. protein) release from hydrogels is one of the most 
important characteristics. In vitro release of lysozyme from the hydrogels fully equilibrated in 
buffered lysozyme solution was studied under conditions simulating the physiological environment. 
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In a typical experiment a hydrogel sample was placed in fresh buffer solution and protein release 
over time was monitored spectrophotometrically at 280 nm. Fig. 7 (b) shows the typical cumulative 
release profiles illustrating lysozyme release from the hydrogels with different HEA content. In the 
case of HEA-rich hydrogels the release profiles for lysozyme show an initial “burst effect”. A 
comparison of 70%- lysozyme release times across the range of HEA-HEMA hydrogel formulations 
(Fig. 7 (c)) shows that the rate of protein release is highly influenced by the composition of the 
hydrogels and remarkably increases with a growth in HEA content. HEA-rich samples (HEA70, 
HEA80) release 70% of total pre-loaded lysozyme in less than 30-40 min, whilst PHEMA and 
HEMA-rich samples (HEA < 40 mol%) release 70% of the lysozyme after more than 3-5 hours. The 
greater release rates in the case of HEA-rich hydrogels are due to significantly higher swelling 
degree (Fig. 1 (a)) and a wide network of interconnecting pores (see Fig. 2) facilitating diffusion of 
the protein molecules. These results are in agreement with the theoretical model of diffusion stating 
that the reduction in the area available for transport of the molecules proportionally reduces the 
diffusion coefficient of solute within the polymer matrix [34]. 
 
The results obtained show that, depending on the application, the co-polymer composition of HEA-
HEMA hydrogels can be adjusted to achieve the desired drug release rate, i.e. fast or sustained 
release behaviour. 
 
Loading into and releasing from hydrogels can cause stress to the protein molecules possibly 
resulting in alteration in their native structure and, consequently, in protein unfolding and 
aggregation. To be considered as a potential carrier for large macromolecules, hydrogels should not 
compromise the conformation and activity of proteins carried. UV-spectroscopy and FTIR were 
used to characterise the secondary structure of lysozyme released from HEA-HEMA hydrogels with 
different HEA content.   
 
Lysozyme released from HEA-rich hydrogels (HEA ≥ 70 mol%) has UV spectra typical for native 
proteins with a peak near 280 nm, a characteristic shoulder at 290 nm, and no absorbance above 310 
nm. The latter evidences that no protein aggregates are formed in solution. The ratios between 
absorbances at 260 and 280 nm (A260/A280) in the UV spectra were 0.6 for untreated lysozyme 
(which is typical for native proteins [35]) and 0.605 ± 0.003 for lysozyme released from HEA70-
HEA90 hydrogels. UV spectra of lysozyme released from HEMA-rich hydrogels (HEA ≤ 60 mol%) 
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were also close to the UV spectrum of native lysozyme with no absorbance at wavelengths above 
310 nm (and hence no aggregation). However, in this case the values of A260/A280 were in the 0.65 – 
0.675 range meaning that the minute alterations to the secondary structure of the protein could occur. 
To make these minor alterations more pronounced, an additional stress has been applied to proteins: 
lysozyme at relatively low concentration (which was kept the same for all samples) in aqueous 
solution, after being released from hydrogels with different HEA content, was processed via 
lyophilisation without cryo- or lyo-protectants. It is known that freeze-drying can cause irreversible 
damage to proteins, especially if freeze-dried formulation does not include protein stabilizers (for 
instance, polymers and/or sugars, buffering salts, etc.) [36, 37]. As a control, a freshly prepared 
lysozyme aqueous solution was freeze-dried. The secondary structure of lyophilised lysozyme was 
analysed using ATR-FTIR spectroscopy.  
 
FTIR is a powerful technique to study structure of proteins, including lysozyme [38]. A typical IR 
spectrum of a protein contains two major bands originated from the peptide groups – amide I and 
amide II bands. The amide I (between 1600 and 1700 cm-1) is the most intense absorption band and 
mainly associated with the stretching vibration of the C=O (70-85%) and C-N (10-20%) groups. The 
exact frequency of the amide I band is determined by the backbone conformation and the hydrogen 
bonding pattern [39, 40]. Amide II band (in the 1510 and 1580 cm-1 region) results from the in-plane 
N-H bending vibration (40-60%) and from the C-N (18-40%) and the C-C (about 10%) stretching 
vibration. This band is sensitive to the protein conformation. To analyse (and even predict) the 
protein secondary structure the amide III region (1220 – 1330 cm-1, in-phase combination of the N-
H bending and the C-N stretching vibrations with small contribution from the C-O in-plane bending 
and the C-C stretching vibration) is also used despite the complicity due to side chain contribution to 
the mode [39 and refs. 166-169 therein]. Amide III mode can be analysed almost without spectral 
deconvolution as the bands of different secondary structures are separated (α-helix 1293-1328, β-
sheet 1225-1250, other – 1257-1288 cm-1 [41]; besides, the absorbance of water is negligible in this 
region.  
 
The FTIR spectrum of untreated freeze-dried lysozyme (Fig. 8, top curve) shows two strong amide I 
and II bands at around 1649 and 1535 cm-1, respectively (Table 1). The FTIR spectra of lysozyme 
released from PHEA and HEA-rich hydrogels (HEA100, HEA80 and HEA70) show only minor 
shifts of the amide I and II band maxima towards higher wavelengths (1652 and 1539 cm-1, Fig. 8). 
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FTIR spectra of freeze-dried lysozyme released from HEMA-rich hydrogels (HEA30 and HEA50) 
reveal more significant spectral alterations – further shifts of the amide I and II bands and decrease 
in their relative intensities. The magnitude of the structural changes clearly correlates with the HEA 
content in hydrogels, i.e.  changes in the IR spectra are more pronounced in the case of lysozyme 
released from HEMA-rich hydrogels. It was previously shown that the lyophilisation-induced 
alterations in the conformation-sensitive amide I region are not a result of water removal from the 
proteins but due to protein unfolding [40]. Overall, the structural changes occurring in the amide I 
and II bands upon lyophilisation of lysozyme released from hydrogels with different HEA content, 
in addition to the minor changes in UV-spectra, evidence some difference between the secondary 
structures of native lysozyme and lysozyme released from HEMA-rich hydrogels. Protein released 
from those hydrogels shows signs of secondary structure alterations amplified as a result of the 
stress applied (freeze-drying in low concentration aqueous solution without protectants). The latter 
confirms a minor damage to the native secondary structure of lysozyme released from HEMA-rich 
hydrogels.  
 
Summarising the first part of our feasibility study, we have to emphasize that relatively stable 
protein (lysozyme) was selected to understand the effect of the protein on the properties of 
hydrogels. In the future research it would be interesting to study less stable proteins which can be 
used for specific therapeutic applications of the hydrogel drug delivery systems.  
 
3.2 Protein aggregation and deposition onto HEA-HEMA hydrogels 
3.2.1 Lysozyme deposition on HEA-HEMA hydrogels  
As it was mentioned above, the long-term contact between hydrogels and proteins can lead to 
protein deposition on hydrogels, the extent of which is shown to be dependent on the time of 
exposure [42]. To study protein deposition on HEA-HEMA hydrogels, the hydrogel samples (HEA 
0, 30, 40, 50, 70 and 80 mol%) were immersed in aqueous or buffered solutions containing 
lysozyme (2 mg/mL). After 1.5 months of storage at 22 °C, the protein deposition on HEMA-rich 
and HEA-rich hydrogels was assessed using SEM. A small amount of separated protein plagues 
(around 3-10 µm) was found on PHEMA and HEMA-rich (30, 40, 50) hydrogel samples (Fig. 9 (a)). 
HEA70 and 80 samples contained only a few small (about 1-6 µm) protein plagues (Fig. 9 (b)). The 
results show that after 1.5 month at room temperature lysozyme forms separated deposits on 
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PHEMA and HEA-HEMA hydrogels; however, the amount of the deposits is relatively low on 
HEMA-rich hydrogels and even less on HEA-rich hydrogels.  
 
The amount of lysozyme loaded into hydrogels after prolonged (1.5 months) incubation of 
hydrogels in the lysozyme solutions with different protein concentrations was measured as described 
above (sections 2.2.6 and 3.1.6). During incubation all samples were kept at 4 °C to minimize 
protein aggregation. For all hydrogels tested the calculated concentrations of lysozyme inside the 
hydrogels were well above the concentration in an incubation solution (i.e. > 100%) (Fig. 10). In the 
case of HEA-rich hydrogels these concentrations were in the range of 150-180 %. More 
hydrophobic HEMA-rich hydrogels absorb significantly more protein (above 200 %) regardless of 
the initial lysozyme concentration in solution. The excessive loading evidences that lysozyme not 
only loaded into but also accumulated by hydrogels in the case of long-term incubation.  
 
Long-term (1 year) incubation of samples in lysozyme solution even at low temperature (4 °C) 
results in massive protein deposition on the hydrogels (Fig. 9 (c - e)). In this case proteins form a 
“network” of plagues on the surface and inside the polymer matrix. It is of interest to note, that for 
all samples (except PHEMA) the areas enriched in protein deposits adjoin the area without protein 
deposits (Fig. 9 (c - e)). Similar to the short-term study, after long incubation in lysozyme solution 
the average amount of protein plagues on HEA-rich hydrogel (HEA80) is seems to be less than on 
HEMA-rich hydrogel (PHEMA and HEA10).  
 
It has been shown previously, that protein deposition on contact lenses is strongly dependent on the 
lens material [21 and references therein]. Materials primary consisting of PHEMA are categorised as 
Group I materials (non-ionic, < 50% water) by the FDA [21] and characterised as low deposition 
level materials. Nevertheless, protein adsorption on the PHEMA-based lenses was found after just 1 
minute contact with tears [20, 43]; after 2 hours of wearing the protein surface coating on PHEMA 
lenses was determined as ~ 10-30 ng/cm2 [44]. Incorporation of some materials (for instance, 
hyaluronic acid) into PHEMA can significantly reduce the degree of protein deposition [45, 46]; at 
the same time other hydrophilic negatively charged monomers (for instance, methacrylic acid, 
MAA) are known to result in significant increase in the amount of deposited lysozyme [47]. Our 
results show that the inclusion of HEA (non-ionic as well as HEMA) into pHEMA matrix increases 
the resistance of hydrogels to protein deposition. Proteins have been shown to express a higher 
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affinity for hydrophobic surfaces than hydrophilic [19], as in this case the entropic gain (due to 
protein dehydration) forces protein adsorption at the surface. In its swollen state PHEMA has been 
shown as being hydrophilic with some hydrophobic properties [48]; thus hydrophobic interaction 
between lysozyme and non-polar parts of PHEMA structure is favourable. As a more hydrophilic 
co-polymer lacking one methyl group, HEA is expected to reduce protein absorption onto hydrogel 
surface what was observed in our experiments (Fig. 9). However these preliminary results require 
additional experimental support, which is outside of the scope of the present work.   
 
3.2.2 Effect of lysozyme deposition on the mechanical properties of HEA-HEMA hydrogels 
The mechanical properties of HEA-HEMA hydrogels fully swollen in PBS buffer without or with 
lysozyme were studied using Texture Analysis. The hydrogel samples were incubated in buffered 
protein solution containing a physiological concentration of lysozyme for a sufficiently long time (~ 
2 months) to allow some protein deposition on hydrogels (as confirmed by SEM). The data show 
that an increase in HEA content results in significant decrease in stress meaning that HEA-rich 
hydrogels are significantly softer than PHEMA and HEMA-rich co-polymer hydrogels and much 
less force is required to deform HEA-rich hydrogels (Fig. S1, a). Even small addition of HEA (10 
mol %) leads to almost 2-times decrease in stress required to compress a hydrogel sample. Loading 
hydrogels with lysozyme and lysozyme deposition onto hydrogels has no significant impact on the 
HEA-HEMA hydrogel mechanical properties (Fig. S1, b).  
 
3.2.3 Aggregation of lysozyme in solution in the presence of HEA-HEMA hydrogels 
It is known that protein unfolding and aggregation can be induced or catalysed by many external 
factors. Contact with hydrogel surface and mechanical stress during loading/release can potentially 
disturb the protein native conformation and facilitate the aggregation. To assess the effect of HEA-
HEMA hydrogels on the protein aggregation, the hydrogel samples were incubated in solutions 
containing lysozyme at room temperature. Lysozyme aggregation in time was analysed and 
quantified using turbidimetry at 360 nm assay, ThT assay, SEM and light microscopy.  
 
Fig. 11 shows the values of optical density at 360 nm (OD360) for lysozyme solutions incubated in 
the presence of different HEA-HEMA hydrogels. As a control, the aggregation of lysozyme in the 
buffer solution without hydrogels was used. As expected, prolonged incubation of lysozyme in 
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solution causes an increase in the optical density at 360 nm for all samples due to protein 
aggregation. However, the increase in OD360 is more pronounced in the presence of HEMA-rich 
hydrogels (Fig. 11). As the turbidimetry assay being based on the total amount of scattering particles 
is a non-specific method and the results can be compromised by the presence of small hydrogel 
fragments in solution, Thioflavin T (ThT) assay was performed to attribute the increase in the 
optical density at 360 nm to protein aggregation. It is known that ThT fluorescence emission is 
increased substantially in the presence of protein amyloids/aggregates but not in the presence of 
natively folded proteins or small hydrogel fragments in solution [49]. Our results from the ThT 
assay confirms the presence of lysozyme aggregates in all solutions tested (data not shown) as the 
increase in ThT fluorescence emission observed was correlated with the increase in OD360. The 
lysozyme aggregation is found to be irreversible (data not shown). The presence of protein 
aggregates was also detected using scanning electron and light microscopy. 
 
Overall, the data obtained show that the irreversible lysozyme aggregation occurs as a result of 
prolonged incubation of lysozyme in solution. Protein aggregation increases in the presence of 
hydrogels with low and intermediate HEA content (HEA < 60 mol %), whilst HEA-rich hydrogels 
(HEA ≥ 70 mol %) have little or no effect on the degree of lysozyme aggregation in solution.  
 
As it is mentioned earlier, proteins are able to absorb to the surfaces and show higher affinities for 
hydrophobic surfaces than hydrophilic. Proteins deposited on hydrogels exhibit conformational 
changes that may result in protein destabilization and denaturation [50, 51]. For instance, it was 
shown that albumin binds irreversibly and denatures within one hour of exposure to hydrogels [51]. 
More favourable interaction with more hydrophobic hydrogels means that lysozyme interaction and, 
as a result, its denaturation and aggregation is going more intensively in the presence of HEMA-rich 
hydrogels. Besides, the enlarged interconnected network of pores formed in HEA-rich hydrogels 
(Fig. 2) favours protein migration/diffusion inside the hydrogels and reduces the damaging stress 
thus impacting the stability of loaded and deposited proteins. This conclusion is supported by our 
results on lysozyme loading into the hydrogels with different HEA content showed above (Fig. 10) 
which evidence the increased absorption of lysozyme by HEMA-rich hydrogels. We also have 
shown that lysozyme released from HEMA-rich hydrogels is (to some extent) destabilised and can 
be damaged and aggregated if an additional stress is applied (see Fig. 8). 
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4. CONCLUSIONS 
In the present work the interaction of HEA-HEMA hydrogels with a model small protein (lysozyme) 
was studied to assess the potential applications of these hydrogels as a drug delivery system for 
sustained release of protein therapeutics. Our results show that copolymerisation of HEMA and 
HEA monomers allows controlling the physicochemical properties of hydrogels (equilibrium 
swelling degree, morphology, mechanical strength, water retention and the rate of therapeutic agent 
release) while loading with protein has very little impact on these properties. An increase in 
effective pore network due to more hydrophilic HEA introduction promotes diffusive penetration of 
lysozyme and increases protein loading rate. Varying the HEA-HEMA hydrogel composition, a 
desirable protein release time can be achieved. The HEMA-rich hydrogels are more suitable for 
sustained release drug, but have an impact on the proteins stability in the case of long-term 
incubation. Proteins released from hydrogels with intermediate and high HEA content preserve their 
native conformation. Additionally, the drug release time can also be regulated by modification of the 
swelling medium, i.e. using more viscous liquid (e.g. water-glycerol/PEG solutions) to get slower 
diffusion of drug from the hydrogel. For biological macromolecules (proteins) this approach is not 
always straightforward as glycerol and PEG are able to alter the protein activity; however, in the 
case of many proteins (according to the published data) these solvents can be added to the medium 
without compromising the proteins. An advantage of the co-polymer hydrogel is that it can be 
designed with the optimal composition of monomers to achieve the desirable drug release with no 
effect on the protein.  
 
Introducing HEA into the hydrogel matrix can also slightly decrease the lysozyme deposition on 
hydrogels. After both short- and long-term incubations, the level of lysozyme deposition on more 
hydrophobic HEMA-rich hydrogels was higher than on hydrophilic HEA-rich hydrogels. Overall, 
our feasibility study shows that HEA-HEMA hydrogels can potentially be used as a drug delivery 
system for large biopharmaceuticals (including proteins) as even low addition of the HEA co-
polymer can significantly increase the amount of imbibed protein and at the same time considerably 
reduce the unwanted protein deposition on the hydrogels.  
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Table 1. Amide I and Amide II bands maxima wavenumbers and relative intensities (strong, 
medium or weak) for freeze-dried lysozyme released from hydrogels with different HEA content.  
 
Lysozyme Amide I band, cm-1 Amide II band, cm-1 
untreated 1649 strong 1535 strong 
Released from:   
HEA30 1657 weak 1543 weak 
HEA50 1653 medium 1539 medium 
HEA70 1652 strong/medium 1537 strong/medium 
HEA80 1652 strong 1539 strong 
HEA90 1652 strong 1537 strong 
HEA100 1652 strong 1535 strong 
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Fig. 1. HEA-HEMA hydrogel swelling in aqueous and in buffer solutions containing lysozyme. 
(a). The equilibrium swelling degree as a function of the HEA co-polymer content for HEA-HEMA 
hydrogels fully swollen in aqueous solution (1) and in 150 mM PBS buffer (pH 7.4) containing 10 
mg/ml lysozyme (2). 
Insert: Typical swelling kinetics curves for HEA-HEMA hydrogels in PBS buffer containing 
lysozyme (curves for HEA50 and HEA80 samples are shown, dry sample weights 25 ± 2 mg). 
(b). Values of the diffusion exponent n for hydrogels swelling in water (1, data from (Hackl et al., 
2015)) and in PBS buffer containing lysozyme (2).  
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Fig. 2. SEM micrographs (x1000) of the porous structure of HEA-HEMA hydrogels equilibrated in 
150 mM PBS buffer containing lysozyme (10 mg/ml). HEA content, mol%: (a) 0, (b) 30, (c) 50, (d) 
70. 
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Fig. 3. TGA measurements of the total amount of liquid phase in HEA-HEMA hydrogels with 
different HEA content.  
(a). Typical TGA thermograms of HEA-HEMA hydrogels loaded with lysozyme. 
(b). Dependencies of the total amount of water in hydrogels on HEA content. Hydrogels were fully 
loaded with lysozyme (1, 2) in either buffered (1) solutions (150 mM PBS, pH 7.4, 10 mg/ml 
lysozyme) or aqueous (2) solution (pH 6, 20 mg/l lysozyme) at 4°C during 2-3 weeks; (3) – 
hydrogels were equilibrated in 150 mM PBS buffer without lysozyme. Solid lines represent fitting 
of the experimental data to sigmoidal (Boltzmann) function using Origin Microcal software.  
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Fig. 4. Water retention properties of HEA-HEMA hydrogels studied by TGA 
(a). Typical “loss-on-drying” TGA curves illustrating change in hydrogel weight over time for 
HEA-HEMA hydrogels in 150 mM PBS buffer containing 10 mg/ml lysozyme. Hydrogel samples 
were incubated at 37 °C during 120 min; after 120 min hydrogels were heated up to 250 °C (120- 
150 min time interval). HEA content (mol%) from top to bottom: 10, 20, 30, 40, 50, 70, 90. Insert: 
example of inflection point calculation using “Onset” option, TGA Pyris software (illustrated for 
HEA50 sample). 
(b). Weight loss (% of the total weight loss) during 120-min incubation at 37 °C for hydrogels with 
different HEA content equilibrated in water (1) or in 150 mM PBS buffer containing 10 mg/ml 
lysozyme (2). Solid lines – fitting of the experimental data to sigmoidal (Boltzmann) function.  
Insert: Representative dependencies of the weight loss% on the lysozyme concentration in the 
swelling medium for PHEMA and HEA50. Solid lines – fitting of the experimental data to linear 
function. 
(c). Dependencies of the percentage of “fast” evaporating water on the HEA content for hydrogels 
fully equilibrated in buffered solution with (1) or without (2) lysozyme. Solid line – fitting of the 
experimental data to sigmoidal (Boltzmann) function.  
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Fig. 5. DSC analysis of the thermal properties of water in HEA-HEMA hydrogels loaded with 
lysozyme.  
(a) Typical DSC thermograms representing the freezing and subsequent melting curves for 
hydrogels equilibrated in 150 mM PBS buffer containing lysozyme (10 mg/ml).  
(b) Enthalpies of melting, ΔH, for freezing water in hydrogels with different HEA content fully 
equilibrated in lysozyme solution. Solid line – fitting of the experimental data to sigmoidal 
(Boltzmann) function.  
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Fig. 6. Amount of freezing water (% of the total water) in HEA-HEMA hydrogels with different 
HEA content equilibrated in buffered solution containing lysozyme (10 mg/ml). Solid line  – fitting 
of the experimental data to linear function; Dash line  – best fit for the amounts of freezing water in 
hydrogels fully swollen in water (data from (Hackl et al., 2015)).  
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Fig. 7. In vitro lysozyme loading into and release from HEA-HEMA hydrogels with different HEA 
content.  
(a). Estimated lysozyme concentrations in hydrogels (relatively to the lysozyme concentration in 
solution) vs. loading times (times of hydrogel incubation in buffered solution containing lysozyme 
(150 mM PBS, pH 7.4, 5 mg/ml of lysozyme, 4 °C)). HEA contents (0, 20, 60, 80) are indicated at 
the top. 
(b). Release profiles for lysozyme. HEA content, mol%: 1 – 20, 2 – 30, 3 – 50, 4 – 80. Before the 
experiment the hydrogels were soaked in 150 mM PBS buffer containing 10 mg/ml lysozyme at 
4 °C for 2-3 weeks. 
(c). Dependencies of the times of 70% lysozyme release on the HEA content in hydrogels. Line is 
guide to the eyes only. 
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Fig.  8. ATR- FTIR spectra of freeze-dried lysozyme from freshly prepared aqueous solution (top) 
and released from HEA-HEMA hydrogels with different HEA content. All peak intensities were 
normalised to the intensity of the peak at 1260 cm-1. Peak around 1724 cm-1 is due to residual HEA 
material.  
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Fig. 9. SEM micrographs of the protein deposits on HEA-HEMA hydrogels immersed in 150 mM 
PBS buffered solution containing lysozyme (10 mg/ml) during 1.5 month ((a) & (b), x5000) at room 
temperature (22 °C) or during 1 year at 4 °C ((c)-(e), x2500)). HEA content, mol%: (a) 0, (b) 70, (c) 
10, (d) 50, (e) 80. 
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Fig. 10. Dependencies of the estimated lysozyme concentrations in hydrogels (relatively to the 
lysozyme concentration in solution) on the lysozyme concentration in solution used to incubate 
hydrogels in. HEA content, mol%: 1 – 50, 2 – 70. Hydrogels were incubated in buffered (150 mM 
PBS, pH 7.4) lysozyme solution at 4 °C during 45 days.  
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Fig.  11. Optical densities at 360 nm for lysozyme solutions (150 mM PBS buffer, pH 7.4, 2 mg/ml 
lysozyme) incubated for 1 day (dark columns) and 2 months (grey columns) with hydrogel 
fragments inside. Left sample (marked “-“) – lysozyme solution incubated in the absence of 
hydrogels.  
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Fig. S1.. Mechanical properties of HEA-HEMA hydrogels in buffer with / without lysozyme.  
(a). Representative force vs. time curves for HEA-HEMA hydrogels in 150 mM PBS buffer 
containing 2 mg/ml of lysozyme. HEA content, mol% (from top to bottom): 0, 10, 30, 40, 70, 90. 
Hydrogels were incubated in solution containing lysozyme at room temperature 1 month before 
measurements.  
(b). Dependence of the stress on HEA content for hydrogels fully swollen in 150 mM PBS buffer 
without (1) or with (2) lysozyme.  
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